Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy: Bristol-Myers Squibb in the cancer field and Novo Nordisk in the inflammation signs. Net sales break down by source of income as follows:
- income from partnership and licensing agreements (74.9%);
- federal subsidies (25.1%).
At the end of 2013, the company had a portfolio of 5 products under development (including 2 clinical development for the oncological).